BERKELEY, Calif., June 28, 2018 /PRNewswire/ -- PRESS RELEASE -- Dr. Andrew Rosenstein, CEO of Steep Hill Pennsylvania, a licensed cannabis testing lab in Pennsylvania, has announced it received ISO/IEC 17025:2005 accreditation by A2LA, an international accrediting agency recognized by governments and industry participants around the world as the standard of excellence for the operation of a quality laboratory management system.
Rosenstein said in making the announcement on the achievement of the Certificate of Accreditation, "We are proud to be a cannabis lab licensed in the State of Pennsylvania, and achieve ISO accreditation, as well. Industry businesses, medical professionals, state regulators and patients can be confident that our lab and its testing standards will operate to the highest international standards. This is a turning point for the industry–recognized industry standards at the highest level with internationally recognized certification. I am very proud of our scientific team's professionalism and hard work to achieve this accreditation."
Jmîchaele Keller, President and CEO of Steep Hill remarked, "Dr. Rosenstein and his scientific team have accomplished a Herculean task of ISO accreditation in three months or less. It is remarkable that Steep Hill Pennsylvania achieved ISO accreditation prior to being licensed to test cannabis—this is a monumental achievement and we are very proud that Dr. Rosenstein's team implemented Steep Hill SOPs and best practices to achieve the highest testing standards, which insures that Pennsylvania patients will have access to the medicine they need and deserve. This is the power of Steep Hill."
Steep Hill Pennsylvania will run full-service testing for cannabinoid profiles (potency), terpenes, pesticides, heavy metals, biological screening and residual solvents, testing for 10+ cannabinoids and 40+ terpenes. Testing for industry businesses is structured for both affordability and quick turnaround times.
